w3badmin

There are a lot of major advancements linked to biological medicines, including many pathological conditions such as autoimmune diseases and cancer. Biosimilars, a lower cost alternative to many biological medicines, have boosted patient access to a lot of these modern therapies. This is something that’s likely to boost even further, especially as therapies requiring biosimilars

The COVID-19 pandemic had a huge impact on the pharmaceutical industry; it disrupted supply chains, delayed production and led to a shortage of medicines. In fact, it’s estimated that close to half of acute care medicines – which includes antibiotics, sedatives and blood thinners – were low in supply during the peak of the pandemic.

If you think there’s too much red tape in your industry, spare a thought for pharma. Pharma manufacturers are subject to 76,000 restrictions–and with patients’ lives on the line, they need to take every one of them seriously. What can other industries learn from how pharma ensures compliance with all these regulations and still maintains

Back in 2020, the worldwide pharmaceutical market had a value of $1.27 trillion; $387.92 billion and $28.235 billion of this was made up of the generics market and biosimilars market respectively. This is set to grow considerably by 2025, with researchers estimating that the global pharmaceutical market could reach $1.7 trillion by then. It’s also